It is the second agreement in the ADC category for BMS in the last few weeks, coming after a smaller $180 million partnership with Orum Therapeutics on an ADC in the protein degrader class with ...

and Orum Therapeutics, which licensed a DAC to Bristol-Myers Squibb in a $180 million deal last year. MSD has started a phase 3 trial of ROR1-directed ADC zilo-V as a treatment for previously ...

After hours: February 7 at 5:11:42 PM EST Loading Chart for IPSC ...

Dyne Therapeutics Inc.-5.60% $1.56B ...

After hours: February 7 at 5:14:26 PM EST Loading Chart for HRTX ...

Sanofi S.A. Part Cert 0.02% €8.03M ...

Meet the young professionals who will be paving the way for the city for years to come.… The search for a permanent chancellor has been ongoing for 10 months.… The founders of Occupi started ...